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Metronidazole (MTZ) is widely used as the standard antibiotic for the treatment of rosacea and, more 
recently, is being used off label in Brazilian hospitals for the treatment of wounds. Following oral 
administration, minimal amounts of active agent reaches the skin and side effects are strongly induced. 
Consequently, MTZ is currently being applied topically in order to improve the therapeutic efficacy with 
reduced side effects, with Rozex® (RZ) (an MTZ gelled formulation) being the only marketed product. 
This study examined whether the use of MTZ 0.75% from thermogel formulations could improve drug 
retention and reduce dermal exposure compared to that by Rozex®. Following a 21 h permeation study, 
the highest total amount of MTZ permeated through the rat healthy and disturbed skin was seen with 
Rozex®, but similar to all formulations regardless of the skin condition. On the other hand, the amount 
retained in the epidermis/dermis was larger for thermogel formulations; at least 4 fold that of Rozex®, 
when the stratum corneum was present as a barrier. In conclusion, thermogel formulations can be favorable 
alternatives to Rozex® for the topical application of MTZ with improved efficacy and reduced side effects.




5-nitroimidazole), a synthetic nitroimidazole derivative, is 
a known antiprotozoal and antibacterial agent. Despite 50 
years of clinical use, MTZ is still considered the standard 
antibiotic for the treatment of anaerobic infections 
(Freeman, Klutman, Lamp, 1997; Löfmark, Edlund, Nord, 
2010). This drug is also widely used for the treatment of 
rosacea, a chronic skin condition that can occur at any 
age but is most commonly diagnosed in women between 
30 and 50 years of age (Fuller, Martin, 2012; Jelvehgari, 
Montazam, 2011). Meanwhile, MTZ is being used off 
label in Brazilian hospitals for the treatment of wounds. 
Following oral administration of MTZ, minimal amounts 
of active agent reaches the skin and side effects are 
strongly induced (Yu et al., 2014). Consequently, MTZ 
is currently being applied topically in order to improve 
the therapeutic efficacy with reduced side effects of the 
drug, with Rosex® (RZ) (an MTZ gelled formulation) 
being the only marketed product (Altinyazar et al., 2005)
chronic dermatosis that requires long-term therapy. 
Oral isotretinoin and topical and/or oral antibiotics are 
effective, but their usage may be limited due to side-
effects. Objective The goal of the study was to compare 
the efficacy of topical adapalene gel (0.1%.
The skin penetration of drugs is a complex process 
usually limited by the stratum corneum (SC) (Herkenne 
et al., 2008; Menon, Cleary, Lane, 2012). According 
to Braddy et al. (2015) “often, even when a topical 
dermatological drug product is systemically absorbed, 
there is no established link between the concentration of 
the drug in the systemic circulation and the therapeutic 
effect”. Thus, for the evaluation of topical drug products, in 
addition to the in vitro release test and in vitro permeation 
E. K. S. Melo, T. P. Araujo, J. W. V. Silva, S. C. C. Chagas, D. C. G. Bedor, D. P. Santana, L. B. Leal
Braz. J. Pharm. Sci. 2017;53(2):e16130Page 2 / 9
study, widely used methodologies include the in vivo 
dermal microdialysis (DMD) and dermatopharmacokinetic 
(DPK) approaches. The DPK procedure (in vivo or in 
vitro), involves measuring drug levels in the layers of SC 
as a function of time post-application and post-removal 
of the product by a tape stripping procedure (Herkenne 
et al., 2006; N’Dri-Stempfer et al., 2008)multiple 
replicate experiments are more easily performed, and 
toxic compounds can be evaluated. MATERIALS AND 
METHODS: Ex vivo experiments on isolated pig ears 
were compared with in vivo studies in human volunteers. 
Four formulations, comprising the model drug, ibuprofen, 
in different propylene glycol (PG.
Taking this into consideration, the aim of this work 
was to develop MTZ topical thermogel products intended 
to decrease penetration and increase MTZ retention in 
disturbed or healthy skin. 
MATERIAL AND METHODS
Chemicals
Metronidazole 0.75% gel (Rozex) was obtained 
from Galderma (Alby-sur-Chéran, France). For the tandem 
mass spectrometry (LC-MS/MS) analysis, metronidazole 
D4 was used as an internal standard (generously provided 
byUMR-S1070 INSERM, Poitiers, France). All chemicals 
used were of analytical grade and solvents were of high-
performance liquid chromatography (HPLC) grade.
Solubility study
For pre-formulation study, the solubility of MTZ 
was determined in different solvents and systems: water, 
propylene glycol (PG), poloxamer 407 (P407) gel, PG/water 
(1:10, v/v), and PG/P407 gel (1:10, v/v). An excess amount 
of metronidazole was added to 5mL of each medium and the 
suspensions were incubated in a shaker at 25 °C for 72 h. 
After this period, the supernatant solutions were centrifuged 
at 605 × g for 30 min. Subsequently, the solutions were 
filtered and the concentration determined by HPLC-UV. 
Topical formulations development
MTZ 0.75% thermogels with and without PG 10%, 
F11 and F12 respectively, were prepared by poloxamer 
dispersion (15%) using an adjustment of the cold method 
(Schmolka, 1972). First, MTZ, methylparaben (0.1%), 
propylparaben (0.05%), and disodium EDTA (0.1%) were 
dissolved in water at 75 °C under magnetic stirring, with 
the exception of F11 (MTZ dissolved in PG). Next, the 
magnetic stirring was stopped and the P407 was added 
at 25 °C. The formulations were kept at 4 °C until clean 
solutions were obtained. 
Rheological analysis
For the rheological behavior evaluation, a 
RI:2:M-H Rheology International viscometer (Rheology 
International Shannon, Shannon, Ireland) was used. 
Measurements of dynamic viscosity (η) were carried out 
at 37 ◦C (normal body temperature) for each formulation 
(15g per sample), at shear rates (γ) between 2 and 200 s−1 
(Ricci et al., 2002; Ricci et al., 2005).
Sol-gel transition temperature
The sol-gel transition temperature was measured 
by a concentric cylinder rotational rheometer (Anton Paar 
MCR 500, Graz, Austria), using Rheoplus® software (v. 
3.40, Anton Paar, Graz, Austria) to collect and analyze data. 
The temperature of the thermogels was increased 
from 20 °C to 45 °C at a heating rate of 1.0°C/min; the 
storage modulus (G’) and the loss modulus (G”) were 
obtained. A graph of G’ and G” versus temperature was 
plotted and the temperature transition was defined as 
where the points of G’ and G” overlapped on the curve 
(Jiang et al., 2016). 
Another technique used to determine the sol-gel 
transition temperature was the visual method. One gram 
of each formulation was placed in a respective glass tube 
and they were immersed in a water bath simultaneously 
with a separate glass tube containing 1.0mL of water. A 
thermometer was placed in the tube with water. Slowly, 
the temperature of the water bath was increased and at 
each degree of variation the glass tube was tipped to an 
angle of 90°. The gelation temperature (t1) was noted 
when the solution in the former stopped flowing at 90°. 
Next, the temperature of the water bath was decreased 
and the temperature (t2) at which the gel flowed again 
was determined. The sol-gel transition temperature was 
calculated by the mean ± S.D. of t1 and t2 (Ur-Rehman, 
Tavelin, Gröbner, 2011).
In vitro permeation study and 
Dermatopharmacokinetic evaluation
The in vitro amount of MTZ permeated through rat 
skin, healthy or disturbed by tape stripping, was evaluated 
using Franz-type diffusion cells (Vision® Microette 
automated diffusion test system, Chatsworth, USA). The 
rat skin was obtained by excision after euthanasia with 
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a lethal dose of isoflurane and posteriorly frozen at – 20 
°C. This phase of the work was carried out in accordance 
with Ethics Committee on Animal Experimentation of 
the Federal University of Pernambuco under agreement 
n. 23076.050654/2015-91. For the disturbed skin, stratum 
corneum was removed following excision using 30 
adhesive tapes (Scotch Book Tape 845, 3M, St. Paul, 
MN). For the experiments, the skin was thawed at room 
temperature and placed on a donor chamber (diffusion area 
of 1.77 cm2). Approximately 166 mg of each formulation 
(corresponding to 0.70 mg/cm2 of MTZ) was applied to 
the skin. The receiver chamber (volume of 6 mL) was 
filled with a phosphate buffer solution (pH 7.4), placed in 
a circulation water bath (36 °C), and agitated in a magnetic 
stirrer (300 rpm). Aliquots (1.0 mL) were withdrawn 
at appropriate time intervals (between 1.0 h and 21 h). 
They were immediately replaced with the same volume 
of fresh receptor. The collected samples were analyzed 
at the end of the experiment (21 h) by LC-MS/MS.MTZ 
concentration in the SC was determined by sequential 
removal of the outer skin layer by tape stripping using 30 
strips one-by-one (Scotch Book Tape, 3M, St. Paul, MN) 
followed by transepidermal water loss (TEWL) evaluation. 
Subsequently, the MTZ was extracted. To evaluate the 
MTZ amount retained in the rest of the epidermis and 
dermis (retention samples), the remaining skin was divided 
into small fractions and MTZ was extracted. Acetonitrile 
(1.0 mL) was added to each tube containing skin pieces 
or tapes. Next, the tubes were shaken for 6 h for MTZ 
extraction and analyzed by HPLC-UV.
Sample analysis (DPK and retention samples)
Determination of MTZ was performed by HPLC-
UV. The LC system employed was a Shimadzu High 
Performance Liquid Chromatography (Shimadzu, Kyoto, 
Japan) with the UV detector set at 320 nm. Reversed-phase 
chromatography was performed on a C18 column (5 µm, 
150 x 4.60 mm ID; Shimadzu, Kyoto, Japan), and a Gemini® 
C18 pre-column (5 µm, 4 x 3 mm ID; Phenomenex, 
Torrance, USA) at 35 °C. The mobile phase was a binary 
mixture of acetonitrile/monobasic sodium phosphate buffer 
20 mM and pH 3.0 (12:88) at a flow rate of 1.0 mL/min and 
injection volume of 20 µL. This procedure was validated 
previously (Araújo, 2016).
Sample analysis (Permeation samples)
Determination of MTZ in permeation samples was 
performed by liquid chromatography coupled with the 
tandem mass spectrometry (LC-MS/MS) method adapted 
from Dubreuil (2005) by UMR-S1070 INSERM (Poitiers, 
France). Reversed-phase chromatography was performed 
on a C18 XbridgeTMBEH300 column (5 µm, 150 x 2.1 mm 
ID; Waters, St-Quentin en Yvelines, France). The isocratic 
mobile phase used was a mixture of acetonitrile/water/
formic acid (25:75:0.1, v/v/v) at a flow rate of 0.16 mL/min. 
The Shimadzu LC System was connected to a SCIEX 
API 3000 MS/MS System operating in the turbo ion spray 
positive mode. The ions monitored in the multiple reaction 
monitoring mode (MRM) were m/z 172.1 (precursor 
ion: [M+H]+) to m/z 128 (or 82) production for MTZ and 
m/z 176.1 (precursor ion: [M+H]+) to m/z 128 (or 82) 
production for MTZ D4 (internal standard). Five microliters 
of permeation samples, standards, or controls were diluted 
with 45 µL of internal standard (0.05 ng/µL in ammonium 
formate 10 mM); 20 µL of this mixture was injected.
RESULTS AND DISCUSSION
Obtainment of F11 and F12 gels
MTZ thermogels (F11 and F12) were developed to 
facilitate drug administration on the skin and in wounds 
because they are in liquid form at room temperature. 
Following the incorporation of MTZ into the vehicle 
and dissolution of P407 by the cold method, odorless 
and colorless solutions (F11 and F12 formulations) were 
obtained at cool and room temperatures. Thermogels are 
free flowing liquid systems at room temperature, become 
gel at the phase transition temperature, and act to sustain 
drug release at physiological temperature (Chen et al., 
2013; Dumortier et al., 2006). 
P407 is an amphiphilic copolymer system consisting 
of ethylene oxide (PEO, hydrophilic) and propylene oxide 
(PPO, hydrophobic) organized in a triblock structure that 
promotes the obtainment of systems with thermo-reversible 
properties (Dumortier et al., 2006). Systems comprised of 
poloxamer polymers offer advantages such as sustained 
drug delivery, local and site-specific action, and comfort 
to patients (Lu et al., 2015). Poloxamer formulations 
have been used for topical, intranasal, ocular, and vaginal 
formulations, as well as for wound application (He et 
al., 2011; Heilmann et al., 2013; Jansen et al., 2013; Li 
et al., 2014; Rossi et al., 2014).This polymer presents 
biological compatibility, non-toxicity, good tolerability, and 
biodegradable properties (Lu et al., 2015).
Solubility study
Both formulations were developed with P407 15%. 
Propylene glycol was added to the F11 gel in order to 
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increase the solubility of MTZ in the system. Among 
the polyvalent alcohols, PG is the most frequently used 
co-solvent in products for topical application (Trommer, 
Neubert, 2006; Patel, Welsh, Baker, 1985). Table I shows 
the solubility values of MTZ at 36 °C in different media. 
The results show high MTZ solubility in the PG compared 
to the other media. 
Sol-gel transition temperature
The measure of sol-gel transition temperature is one 
of the main parameters to be evaluated in thermoreversible 
systems. The gelation of the poloxamer system occurs due 
to the geometric organization (packing) of the micelles 
formed by the dehydration of the PPO blocks, which 
is dependent on the temperature and critical micelle 
concentration (Cabana, Ait-Kadi, Juhasz, 1997; Kabanov, 
Batrakova, Alakhov, 2002).
Figure 1 and figure 2 show the variation of the 
rheological parameters, G’ and G”, of formulations F11 
and F12 as a function of temperature. The temperature 
at which the transition from sol to gel phase occurs was 
verified to be 40.9 °C for F11 and 40.6 °C for F12. This 
shows that the PG alters discreetly the sol-gel transition 
temperature between F11 and F12.
Using the visual method, the values obtained were 
36.5 ± 1.8 °C for F11 and 34.5 ± 1.0 °C for F12. The visual 
method also verifies that the presence of PG in the F11 
formulation increased the sol-gel transition temperature 
compared to that of F12 (P≤0.05). Employing rheological 
techniques are sensible for this analysis; however, the 
visual method is rapid, simple, and less costly for routine 
laboratory measurements.
Figure 3 shows a lower viscosity for F12 than 
for F11 and Rozex® at body temperature (~37 °C). The 
viscosities of F11 and Rozex® were similar. Through this 
data, we also determined the pseudoplastic behavior of the 
formulations observed; the viscosity decreases as the shear 
rate increases (Pereira et al., 2013; Ricci et al., 2002). It 
is worth adding that, in general, formulations containing 
P407 gels offer the advantage of thixotropic behavior. 
This is a desirable characteristic when the intention is 
to facilitate the administration and spreadability in open 
wounds in order to avoid friction of the gel, thus reducing 
the suffering of the patient (Ricci et al., 2002; Pereira et 
al., 2013). The viscosity values apparent at 20 s-1 for the 
thermosensitive gels were 4.4 Pa ± 1.2 for the F12 gel, 
6.5 Pa ± 1.0 for the F11 gel and 7.2 Pa ± 0.6 for Rozex®.
Some products, when added to Poloxamer gels, 
have the capacity to modify their viscosity (Dumortier, 
2006). The PG, included in F11 formulation, helps the 
dehydration of PPO blocks, making the formation of 
TABLE I - Solubility of metronidazole at 36 °C
Solvents mg/mL ± S.D.
Water 9.89 ± 0.64
PG 38.90 ± 11.47
P407 gel 11.75 ± 1.13
PG/water (1:10, v/v) 17.04 ± 2.25
PG/P407 (1:10, v/v) 13.96 ± 2.35
FIGURE 1 - Sol-gel transition temperature measurements for 
F11 gel.
FIGURE 2 - Sol-gel transition temperature measurements for 
F12 gel.
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micelles easier. This stage precedes the gel formation of 
the system. Besides this, regarding Ivanova (2002), the 
presence of the PG decreases the lattice spacing, leading 
to the formation of more compact systems, culminating 
in the increase of the apparent viscosity of the F11 system 
in relation to F12 (Ivanova, Lindman, Alexandridis, 2002; 
Miller, Drabik, 1984; Pereira et al., 2013).
In vitro permeation study and DPK evaluation
Figure 4 shows the total amount (µg/cm2) of MTZ in 
SC from each formulation after 21 h. The average amount 
of MTZ (µg/cm2) retained by the epidermis/dermis from 
healthy and disturbed skin is shown in Figure 5 and 6.
In this study (Figure 4), the statistical evaluation 
(test F) of the amount of MTZ in SC showed that the F11 
compared to RZ, presented statistically similar results (P≥ 
0.05). On the other hand, in the comparison between F12 
and F11 and F12 and RZ statistically significant differences 
were verified (P≤0.05). In other words, a larger quantity 
of MTZ remained in the SC after the application of F12. 
The F11 and RZ formulations contain PG. According to 
the literature, the PG may modify the barrier properties 
in the SC, promoting the passage of the active drug into 
the skin (Patel, Welsh, Baker, 1985; Trommer, Neubert, 
2006). At the same time, as a humectant, PG increases 
stratum corneum hydration, resulting in an increase in 
the drug penetration rate across the skin (Patel, Welsh, 
Baker, 1985).
The retention of MTZ in the epidermis/dermis 
in healthy skin was statistically similar for F11 vs F12 
FIGURE 3 - Viscosity versus shear rate at 37 °C of F11 gel, F12 
gel, and RZ.
FIGURE 4 - Metronidazole amount in the stratum corneum 
after 21 h.
FIGURE 6 - Metronidazole amount retained in epidermis/dermis 
after 21 h - Disturbed skin.
FIGURE 5 - Metronidazole amount retained in epidermis/dermis 
after 21 h - Healthy skin.
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(P≥0.05) but different for RZ (P≤0.05) (Figure 5). 
However, the evaluation in disturbed skin (Figure 6) 
showed that, comparing all formulations, the retention of 
MTZ was similar (P≥0.05). This data demonstrates the 
SC barrier capacity in relation to the permeation of drugs 
(Bolzinger et al., 2012).
A graph of the accumulated amount of MTZ 
permeated through skin versus time for healthy skin 
(Figure 7) and disturbed skin was plotted (Figure 8), 
and the permeation parameters were calculated (Table 
II). Figure 7 shows similar permeation of MTZ through 
healthy rat skin for F11 and F12 formulations (P≤0.05) 
and higher permeation for Rozex®. The average amount 
of MTZ permeated (Q21h) and the flux (J) after 21 h for 
Rozex® in healtly skin was approximately 2 and 4-fold 
higher than for F11 and F12 thermogels, respectively 
(Table II).
As cited earlier, “poloxamer solutions have clearly 
indicated a micellar mode of association” (Yapar, Inal, 
2012). “An important property of these aggregates is their 
ability to incorporate hydrophobic substances that are 
usually insoluble or poorly soluble (as MTZ) in aqueous 
or hydrophilic environment, enhancing their solubility” 
(Bonacusina et al., 2008). A study carried out by Freitas 
et al. (2006) demonstrated that nimesulid salt, being more 
hydrophilic, is supposedly located on the outside of the 
P407 micelles. The MTZ, due to its physicochemical 
characteristics, is probably inserted into the micelles, 
leading to a smaller release of the same in poloxamer gels 
compared with carbopol® gel.
When comparing statistically the MTZ permeation 
after 21h between healthy and damaged skin, no 
statistically significant difference was verified between 
the amount permeated, the flux and the Kp for the three 
formulations (P≥0.05). That is, neither the presence of 
PG nor the use of different polymers (P-407 e carbopol®) 
in the concentration used were capable of influencing the 
permeation of the drug. 
An in vitro permeation study of MTZ through rat 
skin was carried out in two models: healthy skin (Figure 7) 
and disturbed skin (Figure 8). For the disturbed skin, 
stratum corneum was removed by the tape stripping 
method to mimic a wound. To ensure that the entire SC 
was removed, the TEWL was measured (Araújo, 2016). 
The rat skin integrity was evaluated prior to beginning 
the experiments. The receptor solution was analyzed at 
different times up to 21h and replaced with fresh solution. 
FIGURE 7 - Metronidazole amount permeated after 21 h - 
Healthy skin.
TABLE II - Permeation parameters of metronidazole in formulations 
Formulations
Healthy skin Disturbed skin
F11 F12 RZ F11 F12 RZ
Q21h ax 102 (µg) ± S.D. 2.19 ± 1.09 1.30 ± 0.27 4.33 ± 1.28 4.64 ± 1.03 5.57 ± 1.44 9.02 ± 1.27
J b (µg/cm2/h) ± S.D. 5.31 ± 2.43 2.81 ± 0.60 14.10 ± 4.83 10.20 ± 2.34 13.50 ± 3.26 16.80 ± 2.57
Kpc x 10-6± S.D. 0.70 ± 0.32 0.37 ± 0.07 1.88 ± 0.64 1.36 ± 0.31 1.80 ± 0.43 2.24 ± 0.34
Results are expressed as mean ± S.D. a Q21h: MTZ total in medium receptor after 21 h. bJ: MTZ flux after 21 h. cKp: permeability 
coefficient.
FIGURE 8 - Metronidazole amount permeated after 21 h - 
Disturbed skin.
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Next, the SC was analyzed using the DPK approach 
(N’Dri-Stempfer, 2008; Araújo, 2016) and the retention of 
MTZ in the epidermis and dermis was evaluated.
It is notable that the presence of PG was an important 
factor for improving the MTZ transport through the 
SC. However, this excipient was not efficient enough 
to increase the permeation through the whole epidermis 
and dermis. At the same time, the MTZ amount retained 
in the epidermis/dermis was larger for F11 and F12, at 
least 4-fold that of Rozex®, when the SC was present as a 
barrier. Clearly, the presence of the P407 was fundamental 
in increasing the retention of MTZ between epidermis and 
dermis, thus reducing the quantity of MTZ permeated.
CONCLUSION
Considering these results, we conclude that the MTZ 
thermogel topical formulation can be a good alternative to 
improve the application and the efficacy, and to reduce the 
side effects due to the final characteristics of the product, 
to the greater retention and to the lower level of MTZ 
penetration through the skin. However, in order to prove 
this hypothesis, a clinical trial is in progress at the Instituto 
de Medicina Integral Professor Fernando Figueira (IMIP), 
Recife/PE (Brazil), and a microdialysis study in rats is 
being conducted for in vitro/in vivo correlation.
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